�鶹Ů��

Obesity is high and holding steady in the U.S., but the proportion of those with severe obesity — especially women — has climbed since a decade ago, according to new government research. The U.S. obesity rate is about 40%, according to a 2021-2023 survey of about 6,000 people. Nearly 1 in 10 of those surveyed reported severe obesity, the U.S. Centers for Disease Control and Prevention found. Women were nearly twice as likely as men to report severe obesity. (Aleccia, 9/24)

The CEO of Novo Nordisk is set to appear before a Senate panel Tuesday to be grilled on the high cost of Ozempic and Wegovy, the popular drugs used to treat diabetes and obesity. But health economists say it’s unlikely that congressional pressure will be the driving force to get the prices down. (DeGroot, 9/23)

Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday. Jorgensen is set to testify before a Senate committee on Tuesday in a hearing focused on U.S. prices for its widely popular Ozempic and weight-loss drug Wegovy. (9/23)

Recurrent shortages, shifting insurance coverage, patient whims and a lack of longer-term guidance about side effects and dosing have forced doctors and patients to make up as they go what quantity of drugs to take and when. It amounts to a human experiment of trial and error. (Cha, 9/24)

Those who use drugs like Ozempic — either for medical reasons or aesthetic ones — often find the weight loss leads to something now called “Ozempic face.” The result: medical spas are seeing an uptick in requests from clients using medicines like Ozempic, Wegovy, Mounjaro, and Zepbound. (Wellington, 9/23)